Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3687 - Current and future next generation sequencing usage in European molecular oncology diagnostics


10 Oct 2016


Poster display


Christopher Whitten


Annals of Oncology (2016) 27 (6): 526-544. 10.1093/annonc/mdw392


C.M. Whitten1, A. Thum2, T. Blass2

Author affiliations

  • 1 Ivd, dii Healthcare, 04107 - Leipzig/DE
  • 2 Ivd, dii Healthcare, Leipzig/DE


Abstract 3687


The integration of next generation sequencing (NGS) into clinical molecular diagnostic (MolDx) laboratories has been growing and continues to expand into new applications for molecular oncology, but is hampered by technical challenges. In order to better meet the needs of diagnostic testing, it is necessary to understand the current and planned adoption of NGS systems as kits, both commercial and laboratory developed, must be optimized for specific machines.


We surveyed >3000 labs throughout Western Europe and will here focus on NGS usage in general and overall molecular methods for BRCA, BRAF, RAS, and EGFR in Germany (DE), Italy (IT), and the UK. Telephone interviews were conducted in 2015 and 2016 with data collected on technologies, systems and kits used, test volumes, and planned NGS systems and markers in the next 5 years.


Usage of NGS systems is increasing, though this varies by country, with DE being slowest to adopt where only 7% of MolDx labs have an NGS and 50% of systems used for oncology MolDx are still Sanger sequencers. Most molecular oncology done in IT is on RT-PCR (51%) systems, followed by NGS (34%). The UK has the highest NGS usage for oncology (52% of systems). Overall, ∼17% of MolDx labs in Europe have an NGS machine and, of those not currently running NGS, another 21% plan to acquire it in the next 5 years. Sixty-five percent of those reporting a preference chose Illumina systems. There is a growing focus on benchtop sequencers seen in the dominant presence of Illumina's MiSeqs (35%) and Thermo Fisher Ion sequencers (29%) out of all current NGS systems and future planned systems (90% reporting intent to acquire Illumina systems stated this would be a MiSeq).


Current top molecular oncology testing includes EGFR, BRAF, RAS, and BRCA and these will remain widely tested in the near future along with increasing use of multi-gene panels. The popularization of smaller and easier to use NGS systems will help grow clinical NGS usage as they're cheaper and faster but there is still a need for increased automation, more panels, and easier result reporting. As NGS usage in labs becomes standardized and more requested by oncologists, this will push payers to improve reimbursement strategies allowing for improved clinical patient care.

Clinical trial identification

Legal entity responsible for the study

dii Healthcare GmbH: a consulting and market research firm operating solely in the area of in-vitro diagnostics


dii Healthcare GmbH: a consulting and market research firm operating solely in the area of in-vitro diagnostics


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings